Intel stock extends gains after report of possible U.S. government stake
BAD HOMBURG, Germany - Fresenius Medical Care (FME), a provider of products and services for individuals with renal diseases, announced Monday the launch of the first tranche of its share buyback program worth up to €600 million. The company, currently valued at $14.14 billion, has demonstrated strong shareholder returns with a robust free cash flow yield of 17% and a 28-year track record of consecutive dividend payments.
This initial tranche forms part of a larger €1 billion share buyback program that will run until August 10, 2027, as outlined in the company’s new capital allocation framework presented at its Capital Markets Day on June 17. The first tranche is expected to be completed by April 30, 2026.
"With the share buyback program, we are rapidly implementing an important component supporting our new FME Reignite strategy," said Helen Giza, CEO of Fresenius Medical Care, according to the company’s press release.
The company’s CFO Martin Fischer noted that the implementation of regular share buybacks would complement FME’s existing dividend policy as part of its new capital allocation approach.
Fresenius Medical Care operates 3,676 dialysis clinics globally, providing treatments for approximately 300,000 patients. The company is listed on both the Frankfurt Stock Exchange (FME) and the New York Stock Exchange (FMS).
The company stated it will provide regular updates on the progress of the share buyback program on its investor relations website.
In other recent news, Fresenius Medical Care reported its second-quarter 2025 revenue at €4,792 million, aligning with consensus estimates of €4,750 million and reflecting a 5% growth at constant exchange rates. The company’s adjusted EBIT was €476 million, slightly below the anticipated €492 million, influenced by a severe flu season and excess mortality. BofA Securities raised its price target for Fresenius Medical Care to €56.00, maintaining a Neutral rating, following updates on medium-term targets shared during the company’s Capital Markets Day. These targets include a mid-teen EBIT margin by 2030 and a €1 billion share buyback program over two years. Truist Securities reiterated its Hold rating and a $30.00 price target, noting the company’s aim for a midteens adjusted operating income margin by 2030 and projected U.S. treatment growth. Bernstein SocGen Group also increased its price target to $31.50 from $26.00, maintaining a Market Perform rating. This adjustment was made despite a recent 4.5% drop in shares, which Bernstein found surprising given Fresenius Medical Care’s solid financial targets for 2030. These developments provide investors with insights into the company’s financial performance and strategic plans.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.